Clinical Trial

Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer

Name: Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer — clinical trial record (NCT07303881)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: JACKPOT22

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study is a single-arm clinical trial designed to evaluate the safety and efficacy of golidocitinib in patients with refractory, immune-related hematologic toxicity in advanced lung cancer.

Trial Details

NCT Number	NCT07303881
Lead Sponsor	The First Affiliated Hospital of Guangzhou Medical University
Conditions	IrAE, Hematologic Disorder, Lung Cancer (Locally Advanced or Metastatic)
Enrollment	16 participants
Start Date	2026-02
Primary Completion	2027-06 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2025-12-26